Prolotherapy
ApprovedBiologic
Prolotherapy is one of 86 biologic programs targeting Arthritis. It is currently in Approved.
4
Indications
10
Total Trials
1
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Prolotherapy
MMayo Clinic
Approved
Ilaris
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Enbrel
IImmunex
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lateral Epicondylitis3 trials
Prolotherapy2 trials
Caudal Epidural Prolotherapy Versus Steroids in Failed Back Surgery Syndrome
Completed·—·Phase 2/3·NCT05548738·90 enrolled
Osteoarthritis2 trials
Comparison of Effect of Prolotherapy and Paraffin Waxes for Hand Osteoarthritis
Completed·—·N/A·NCT03839108·42 enrolled
Tendinopathy1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prolotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- MMayo Clinic